HEAD-TO-HEAD COMPARISON
Compound Semaglutide vs Compound TirzepatideSemaglutide vs Tirzepatide
Verdict: Compound Tirzepatide (tirzepatide) is a dual GIP / GLP-1 receptor agonist; Compound Semaglutide (semaglutide) is a GLP-1 mono-agonist. In head-to-head and indirect-comparison data, tirzepatide produces larger mean weight loss and stronger HbA1c reduction at maintenance dose. Compound Semaglutide has a longer real-world track record and broader insurance coverage in some plans.
Side-by-side comparison
| Compound Semaglutide | Compound Tirzepatide | |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Manufacturer | 503A / 503B pharmacies | 503A / 503B pharmacies |
| FDA approval | Not approved as finished product | Not approved as finished product |
| Indication | Not an FDA-approved finished product. 503A compounding is restricted now that the FDA has declared the semaglutide shortage resolved. | Not an FDA-approved finished product. 503A compounding is restricted now that the FDA has declared the tirzepatide shortage resolved. |
| Starting dose | Step 1 of 5 | Step 1 of 6 |
| Maintenance target | 2.4 mg/week | 15 mg/week |
| Titration length | ~17 weeks | ~21 weeks |
| Mean weight loss | Same molecule as Wegovy/Ozempic; outcomes track brand when correctly compounded | Same molecule as Mounjaro/Zepbound; outcomes track brand when correctly compounded |
| HbA1c reduction | Same as branded semaglutide | Same as branded tirzepatide |
| Cost (US list) | Historically $200 to $400 / mo during shortage | Historically $250 to $500 / mo during shortage |
| Insurance | Not covered | Not covered |
Who should pick which
- Consider Compound Semaglutide only with a clinician's prescription and a verified Certificate of Analysis from the supplying pharmacy. Cost is meaningfully lower than Compound Tirzepatide but supply has narrowed since FDA shortage resolution.
- Consider Compound Tirzepatide (tirzepatide) if mean weight loss in published trials is the deciding factor. Dual GIP + GLP-1 mechanism produces the largest effect size in head-to-head data.
- Consider Compound Semaglutide for research / off-label use cases; titration completes in roughly 17 weeks.
- Consider Compound Tirzepatide for research / off-label use cases; titration completes in roughly 21 weeks.
Switching between the two
Transitioning between semaglutide and tirzepatide typically restarts titration at the new product's starting dose to manage tolerability. Some clinicians use a one-step-down approach if the prior agent was at maintenance.
Open Semaglutide Dose Calculator → Compare full titration schedules side by sideFrequently asked
Is Compound Semaglutide better than Compound Tirzepatide?
Compound Tirzepatide (tirzepatide) is a dual GIP / GLP-1 receptor agonist; Compound Semaglutide (semaglutide) is a GLP-1 mono-agonist. In head-to-head and indirect-comparison data, tirzepatide produces larger mean weight loss and stronger HbA1c reduction at maintenance dose. Compound Semaglutide has a longer real-world track record and broader insurance coverage in some plans.
Can I switch from Compound Semaglutide to Compound Tirzepatide?
Transitioning between semaglutide and tirzepatide typically restarts titration at the new product's starting dose to manage tolerability. Some clinicians use a one-step-down approach if the prior agent was at maintenance.
Does Compound Semaglutide produce more weight loss than Compound Tirzepatide?
Compound Semaglutide: Same molecule as Wegovy/Ozempic; outcomes track brand when correctly compounded. Compound Tirzepatide: Same molecule as Mounjaro/Zepbound; outcomes track brand when correctly compounded. Direct comparisons depend on dose, duration, and population studied; check the linked trial citations on each brand page for full context.
Why is Compound Semaglutide priced differently from Compound Tirzepatide?
Compound Semaglutide costs Historically $200 to $400 / mo during shortage; Compound Tirzepatide costs Historically $250 to $500 / mo during shortage. Differences reflect manufacturer pricing strategy, FDA indication (obesity-labeled brands often face patchier insurance coverage than diabetes-labeled brands), and whether the product is a finished drug or a pharmacy compound.
Which is better for Type 2 diabetes, Compound Semaglutide or Compound Tirzepatide?
Both Compound Semaglutide and Compound Tirzepatide address T2D-relevant pathways via GLP-1 receptor activity. Trial HbA1c reductions: Compound Semaglutide Same as branded semaglutide; Compound Tirzepatide Same as branded tirzepatide.
Related
For research informational use only. Not medical advice. Compound Semaglutide is a compounded product not approved as a finished drug. Consult a qualified healthcare provider for clinical decisions.